deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06879340

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Sponsor: University of Kansas Medical Center

Conditions B-Cell Non-Hodgkin Lymphoma B-cell Acute Lymphoblastic Leukemia
Interventions Cyclophosphamide (Conditional therapy) DuoCAR20.19.22-D95 Fludarabine (Conditional therapy)
Updated 2 times since 2025 Last updated: Apr 3, 2025 Started: Mar 31, 2025 Primary completion: Mar 31, 2030 Completion: Mar 31, 2040
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on B-Cell Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia, this trial is actively recruiting participants. The trial is conducted by University of Kansas Medical Center and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – present · 14 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. May 2025 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Apr 2025 — May 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Kansas Medical Center
Data source: University of Kansas Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations